What are the recommended steps to achieve catch-up growth in a child with growth retardation?

Catch-Up Growth in Children with Growth Retardation

The primary approach to achieving catch-up growth depends critically on first addressing all treatable underlying causes of growth failure (nutrition, metabolic acidosis, anemia, mineral-bone disorder), followed by growth hormone therapy at 0.045-0.05 mg/kg/day subcutaneously when persistent growth failure is documented (height <3rd percentile AND height velocity <25th percentile). 1

Step 1: Address Underlying Treatable Causes FIRST

Before considering growth hormone therapy, you must optimize:

• Nutritional status: Ensure adequate caloric intake and protein. In infants under 6 months with growth failure, prioritize establishing exclusive breastfeeding; if not feasible, use specialized formulations like F-100D 2
• Metabolic acidosis: Correct with bicarbonate supplementation
• Anemia: Treat to target hemoglobin levels
• Mineral and bone disorder: Manage hyperparathyroidism (PTH must be <500 pg/ml before starting GH) 1
• Electrolyte losses: Replace as needed
• Adequate dialysis (if applicable): Optimize clearance 1

Critical pitfall: Starting GH without addressing these factors first will result in suboptimal response and wasted resources.

Step 2: Define Growth Failure Precisely

Growth failure requiring intervention is defined as BOTH of the following:

• Height below the 3rd percentile for age and sex (height SDS <-1.88)
• Height velocity below the 25th percentile for age and sex

Timing matters: Document persistent growth failure over:

• 3 months in infants
• 6 months in older children and adolescents 1

Step 3: Assess Growth Potential and Rule Out Contraindications

Required assessments before GH therapy:

• Bone age radiograph (left wrist) to confirm open epiphyses
• Fundoscopic examination to rule out papilledema
• Pubertal staging (Tanner stages if >10 years old) 1

Absolute contraindications to GH therapy:

• Closed epiphyses (strong contraindication)
• Active malignancy (strong contraindication)
• Acute critical illness (strong contraindication)
• Severe secondary hyperparathyroidism (PTH >500 pg/ml)
• Proliferative or severe non-proliferative diabetic retinopathy
• Known hypersensitivity to GH or excipients
• Patient/family unwillingness 1

Step 4: Growth Hormone Therapy Protocol

Dosing:

0.045-0.05 mg/kg per day by daily subcutaneous injection 1

Duration:

Continue until:

• Final height is reached (epiphyseal closure), OR
• Renal transplantation (in CKD patients) 1

Expected response:

• First year: Most robust catch-up growth with cumulative height increase of 1.1-1.9 standard deviation scores over 5-6 years 1
• Subsequent years: Growth velocity remains elevated but attenuates compared to first year 1

Factors predicting better response:

• Younger age at treatment initiation
• Greater initial height deficit
• Better residual renal function (if CKD)
• Longer treatment duration 1

Special Populations

Post-Transplant Children:

• Wait 1 year after transplantation before starting GH (moderate contraindication during first year) 1
• Only initiate if spontaneous catch-up growth does not occur
• Consider steroid-free immunosuppression first if feasible (steroid minimization improves height SDS by mean difference 0.38) 1

Children on Dialysis:

• GH response is significantly attenuated compared to pre-dialysis CKD
• Can be improved by augmenting dialytic clearance with daily hemodiafiltration 1

Nephropathic Cystinosis:

• Consider GH at all stages of CKD (not just stage 3-5) due to severe early growth failure from Fanconi syndrome 1

Infants <6 months:

• Infancy is the most sensitive phase for growth-suppressing effects
• Any decrease in growth rate can result in severe, potentially irreversible loss of growth potential
• Act quickly after documenting 3-month period of growth failure 1

Monitoring During GH Therapy

• IGF-1 levels: Maintain at 0 SDS (normal range) during treatment, assuming adequate catch-up growth is occurring 3
• Growth velocity: Track every 3-6 months
• Bone age progression: Monitor annually
• Metabolic parameters: Continue addressing underlying causes throughout treatment

Key Clinical Pearls

The evidence strongly supports early intervention: Delaying GH therapy until severe growth retardation develops requires higher absolute doses (due to increased body weight) and may result in irreversible loss of growth potential, particularly in infants 1.

Normal IGF-1 does not exclude GH deficiency: In children with brain tumors, delayed puberty, or delayed bone age, IGF-1 levels do not accurately predict GH deficiency 3. Clinical context (growth velocity, underlying condition) takes precedence.

Catch-up growth has GH-independent and GH-dependent phases: Initial catch-up may occur without GH, but complete catch-up requires adequate GH levels 4. This underscores why addressing nutritional and metabolic factors first is essential, but GH therapy should not be indefinitely delayed waiting for spontaneous catch-up.